/Companies

Savara

NASDAQ: SVRA

Austin, US · Founded 2007 · Delaware corporation · 125 employees on LinkedIn · 6 known investors

Find your way into Savara

Sign up to see every warm intro you have to Savara

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Savara team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases. The company focuses on novel therapeutic approaches for patients with rare respiratory conditions.

Founders & leadership

MPMatt Pauls
Matt PaulsChair of the Board of Directors and Chief Executive Officer
MC
Mike CieslaExecutive
BCBadrul Chowdhury
Badrul ChowdhuryChief Medical Officer2019–2022Dr. Badrul Chowdhury is a physician with board certifications in Internal Medicine and Allergy and Immunology, and holds a PhD in Immunology. He has led development of small molecule and biologic therapeutics across respiratory, allergy, immunology, and rheumatology indications, with expertise in clinical trial design and regulatory strategy for both common and rare lung diseases.
SJSantosh J. Vetticaden
Santosh J. VetticadenExecutive
GD
Gregory D. GorgasExecutive
PK
Patrick KeranExecutive
BL
Brandi L. RobertsExecutive
RM
R. Martin EmanueleExecutive
BM
Brian M. CulleyExecutive
RJ
Richard J. HawkinsNamed on SEC filing
AV
An van Es-JohanssonNamed on SEC filing
RSRicky Sun
Ricky SunNamed on SEC filingPartner at Bain Capital Life Sciences

Investors · 6

Reported raises · per SEC filings

Form D private placements

$30.9M disclosed across 2 of 3 rounds · 1900–2019

▶$26.8MraisedJan 2020 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard J. HawkinsDirector
  • An van Es-JohanssonDirector
  • Ricky SunDirector
  • Taneli JouhikainenExecutive Officer
  • Mike CieslaExecutive Officer
  • Badrul ChowdhuryExecutive Officer
  • John LordExecutive Officer
  • Peter GinsburgExecutive Officer
  • Kate McCabeExecutive Officer
  • Nevan ElamDirector
  • Joseph S. McCrackenDirector
  • Matthew PaulsDirector
  • David A. RamsayDirector
  • Robert NevilleExecutive Officer, Director
  • David L. LowranceExecutive Officer
Offering amount
$75M
Amount sold
$26.8M
Sales commissions
$1.4M
Placement agents
Evercore Group L.L.C., Jefferies LLC
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedMar 2014 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lewis ShusterDirector
  • David A. RamsayDirector
  • Santosh J. VetticadenExecutive Officer
  • Gregory D. GorgasExecutive Officer
  • Patrick KeranExecutive Officer
  • Jack LiefDirector
  • Brandi L. RobertsExecutive Officer
  • R. Martin EmanueleExecutive Officer
  • Brian M. CulleyExecutive Officer, Director
Offering amount
$4.2M
Amount sold
$4.2M
First sale
Feb 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

Companies working in the same space as Savara.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2013$4M
National Institutes of Health (NIH)National Institutes of HealthPhase I2013$190.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$149.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$184.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Savara do?
Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases. The company focuses on novel therapeutic approaches for patients with rare respiratory conditions.
Who are Savara's investors?
Savara's investors include Bain Capital Life Sciences, Central Texas Angel Network, Green Park & Golf Ventures, Keiretsu Forum, Moore Venture Partners, New Enterprise Associates (NEA).
How much funding has Savara raised?
Savara has disclosed $30.9M raised across 2 of its 3 known rounds.
Where is Savara headquartered?
Savara is headquartered in Austin, US.